As per MRFR analysis, the Shingles Vaccine Market Size was estimated at 3.64 (USD Billion) in 2023. The Shingles Vaccine Market Industry is expected to grow from 3.89(USD Billion) in 2024 to 8 (USD Billion) by 2035. The Shingles Vaccine Market CAGR (growth rate) is expected to be around 6.78% during the forecast period (2025 - 2035).
The Global Shingles Vaccine Market is influenced by significant market drivers, primarily the aging population and increasing awareness about the health risks associated with shingles. As people age, they become more susceptible to shingles, prompting health authorities across various countries to recommend vaccinations. This demographic change is expected to bolster demand for shingles vaccines globally. Furthermore, the rise in healthcare expenditure and enhanced access to vaccinations through public health initiatives also contribute as crucial drivers in this market. Recent trends indicate a growing shift towards more effective and easier-to-administer vaccines.
Formulations that need to be taken less frequently are becoming popular due to improved patient adherence. Moreover, the introduction of new technologies like mRNA in vaccine production will transform the shingles vaccine market because they can be developed more quickly and likely more effectively. The other important trend is the greater focus on preventative healthcare and the concern of governments and health agencies on reducing the burden of this painful affliction through vaccinations. Additionally, there are new markets in developing countries as healthcare systems are enhanced and the accessibility of vaccines increases.
There is also an opportunity for pharmaceutical companies to invest in educational campaigns aimed at both healthcare providers and the general public to enhance understanding of shingles and the importance of vaccination. Overall, staying aligned with these trends and leveraging emerging opportunities could be pivotal for stakeholders in the Global Shingles Vaccine Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Global Shingles Vaccine Market Industry is positioned for growth due to the rapid increase in the elderly population. As per the World Health Organization, the global population aged 60 years and older is expected to reach 2.1 billion by 2050, nearly doubling from 1 billion in 2020. This demographic is particularly at risk for shingles, given that the incidence of the disease increases with age. Health authorities, such as the Centers for Disease Control and Prevention, recommend vaccination for individuals aged 50 and above, creating a large and growing target market for shingles vaccines.
As more older adults seek preventive measures like shingles vaccines, the demand is expected to rise significantly, propelling market growth. Additionally, the involvement of established organizations focusing on age-related health issues assures ongoing advancements in vaccine development, further enhancing market prospects.
There is a notable increase in awareness about shingles and its potential complications, which is significantly driving the Global Shingles Vaccine Market Industry. Campaigns led by health organizations and governments are on the rise to educate the public regarding the symptoms and risk factors associated with shingles. For instance, the National Institutes of Health reported in their recent outreach endeavors that awareness campaigns have resulted in a 30% increase in inquiries regarding the shingles vaccine over the past five years.This rise in public awareness prompts more individuals to get vaccinated, especially older adults, thereby fostering growth in the market.
Technological advancements in vaccine development are proving instrumental to the growth of the Global Shingles Vaccine Market Industry. The U.S. Food and Drug Administration continues to approve innovative vaccines that enhance efficacy and reduce side effects, significantly impacting public acceptance and uptake. Recent advancements have led to the creation of vaccines that offer improved immune responses with fewer doses required. According to data from the pharmaceutical sector, novel live-attenuated vaccines have shown up to a 97% efficacy rate in preventing shingles.Such impressive results encourage more people to undergo vaccination, driving market expansion.
Significant improvements in healthcare infrastructure globally contribute positively to the Global Shingles Vaccine Market Industry. Many governments are investing heavily in healthcare initiatives to enhance the delivery of vaccinations, making them more accessible to the public. For instance, substantial funding allocated by the Global Fund has led to a considerable increase in vaccination programs across several countries, especially in regions with previously low vaccination rates.Reports indicate that improved healthcare access has resulted in a 25% rise in vaccination rates among older adults in developing countries in the last decade, illustrating the potential for market growth as accessibility increases.
The Global Shingles Vaccine Market is experiencing significant growth fueled by increasing awareness about shingles and the severe complications associated with the disease, contributing to robust demand for various vaccine types. In 2024, the revenue generated from the overall market reached 3.89 USD Billion, with projections of reaching 8.0 USD Billion by 2035, showcasing a clear upward trajectory.
The segmentation of the Global Shingles Vaccine Market by Vaccine Type reveals key insights regarding Live Attenuated Vaccine, Recombinant Vaccine, and Subunit Vaccine.The Live Attenuated Vaccine is pivotal in this sector, held a market valuation of 1.35 USD Billion in 2024 and is expected to increase to 2.5 USD Billion in 2035; its wide adaptability, high efficacy rates, and established safety profile contribute to its majority holding within the market.
The Recombinant Vaccine segment also played a vital role, valued at 1.85 USD Billion in 2024 and is anticipated to grow to 3.5 USD Billion by 2035, showing a strong preference among healthcare providers due to its targeted approach and enhanced immune response, which is significant in preventing shingles.On the other hand, the Subunit Vaccine, although smaller in comparison, reported a value of 0.69 USD Billion in 2024, projected to escalate to 2.0 USD Billion in 2035, reflecting its recent introduction to the market and increasing adoption in clinical settings as an effective preventive measure.
These variations highlight distinct trends and preferences driving the market; while Live Attenuated Vaccines dominate due to their historical use and effectiveness, Recombinant and Subunit vaccines are carving out their segments based on technological advancements and patient safety concerns, thereby creating opportunities for innovation and strategic collaborations to further enhance market growth within the global landscape.As patient demographics continue to evolve and healthcare systems prioritize preventive care, the Global Shingles Vaccine Market is set to thrive, with each vaccine type presenting unique benefits and growth potential, reflecting shifting healthcare needs and advancements in immunization strategies.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Global Shingles Vaccine Market is experiencing robust growth, particularly when viewed through the lens of age demographics. In 2024, the market was valued at 3.89 USD Billion, reflecting the increased awareness and uptake of vaccines among older populations. The Age Group segmentation is crucial, with individuals aged 50-59 years playing a significant role in market dynamics, as they represent a growing portion of the population at risk for shingles.
The 60-69 years cohort is also noteworthy, as their susceptibility to complications from shingles reinforces the need for vaccination.Additionally, those aged 70 years and above are the primary beneficiaries of shingles vaccines due to their heightened risk factors, thus dominating the market in terms of demand.
The population aged 50 years and above is demonstrating higher healthcare engagement, driven by an increasing focus on preventive care and the recognition of shingles' impact on quality of life. This age group is also a prime target for health campaigns aimed at raising awareness about the benefits of vaccination. The Global Shingles Vaccine Market data forecasts a valuation of 8.0 USD Billion by 2035, driven by rising incidences of shingles and supportive healthcare policies promoting vaccination for older adults.Overall, the market growth in age-based segmentation reflects broader trends in public health prioritizing vaccination among vulnerable populations.
The Administration Route segment of the Global Shingles Vaccine Market plays a crucial role in shaping the delivery of immunization against shingles. As the overall market was valued at 3.89 USD Billion in 2024, this segment contributes significantly to the market dynamics. The segment includes various methods, with Subcutaneous, Intramuscular, and Intravenous being prominent techniques.
The Subcutaneous route typically allows for quicker absorption and benefits from a wider range of healthcare settings, making it essential in increasing vaccination accessibility.Intramuscular administration is also significant as it is commonly used in vaccinations, ensuring a robust immune response, which the Global Shingles Vaccine Market heavily relies on.
Intravenous routes, while less common for vaccines, provide an alternative method for specific patient populations who may require immediate immunity boosts. As the market evolves, understanding these distinct administration routes becomes vital for addressing healthcare challenges and improving vaccination rates, thus contributing to the overall market growth and fulfilling public health objectives.The expected growth trends are supported by increasing awareness regarding the vaccine's benefits, ongoing research initiatives, and the aging global population, all driving the necessity to enhance immunization strategies.
The Global Shingles Vaccine Market has been experiencing substantial growth, particularly within the End User segment, which consists of Hospitals, Clinics, and Pharmacies. In 2024, this market was valued at approximately 3.89 USD Billion, driven by increasing awareness of shingles and the importance of vaccination in preventing complications associated with the disease. Hospitals play a crucial role in administering the shingles vaccine, with extensive facilities and healthcare professionals being key to successful immunization efforts.Meanwhile, Clinics contribute significantly by providing accessible vaccination options to a broader population, making them essential for reaching at-risk groups.
Pharmacies also hold a significant share of this market due to the convenience they offer to consumers, allowing for easier access to vaccines without the need for appointments. The shift towards more convenience and accessibility in these settings has positively influenced the market growth and uptake of vaccines. With a clear focus on this segment, investments in healthcare infrastructure and patient education are anticipated to further drive the Global Shingles Vaccine Market revenue in the coming years.Market statistics indicate that expanding access and raising awareness about the benefits of shingles vaccination among different age groups will enhance overall market dynamics.
The Global Shingles Vaccine Market exhibits significant regional segmentation, reflecting diverse valuations and market dynamics. In 2024, North America led with a market value of 1.472 USD Billion, anticipated to grow to 3.077 USD Billion by 2035, highlighting its majority holding in the overall market due to an aging population and extensive healthcare accessibility. Europe followed with a valuation of 0.875 USD Billion in 2024, growing to 1.934 USD Billion by 2035, driven by increasing awareness and vaccination programs.
The APAC region was valued at 0.676 USD Billion in 2024 and is expected to reach 1.407 USD Billion by 2035, emerging as a crucial market due to rising disposable incomes and healthcare investment.South America, though smaller, grew from 0.398 USD Billion in 2024 to 0.703 USD Billion in 2035, driven by an expanding healthcare infrastructure. Meanwhile, the MEA region, valued at 0.469 USD Billion in 2024, is projected to increase to 0.879 USD Billion by 2035, with growth influenced by increasing vaccination initiatives. This varied segmentation underscores the Global Shingles Vaccine Market's potential, with each region presenting unique growth opportunities and challenges shaped by demographic trends and healthcare policies.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Global Shingles Vaccine Market is characterized by dynamic growth driven by increasing awareness of shingles, a reactivation of the varicella-zoster virus, particularly among aging populations. Competitive insights reveal a landscape that involves several key players strategizing to enhance their market share through innovative product offerings, strategic partnerships, and robust marketing campaigns aimed at education and prevention.
The market is significantly shaped by factors such as the availability of vaccines, regulatory approvals, safety profiles, and efficacy rates, alongside the rising healthcare expenditures across various regions. With an emphasis on patient-centric approaches, companies are focusing on building relationships with healthcare professionals and leveraging digital platforms to reach wider audiences, making the competitive environment both attractive and challenging.
Merck and Co. has established itself as a formidable player in the Global Shingles Vaccine Market with its well-regarded vaccine portfolio, particularly focusing on the development and distribution of its shingles vaccine. The company benefits from a robust R&D pipeline that emphasizes innovation in vaccine technology, enabling the delivery of effective preventive solutions. Merck's global presence allows it to leverage extensive distribution networks and collaborative initiatives with healthcare providers, which enhances its visibility and accessibility. The company’s strong reputation for quality and safety bolsters consumer trust, making it a reliable choice for patients and healthcare professionals alike.
Moreover, Merck's strategic investments in marketing and education programs further reinforce its position by promoting awareness about shingles and the importance of vaccination.Pfizer is another key player in the Global Shingles Vaccine Market, recognized for its extensive research capabilities and broad product offerings. The company has focused on developing vaccines that address various infectious diseases, including shingles, and has made significant strides in global market penetration. Pfizer's strengths lie in its capacity to leverage its global infrastructure, allowing for efficient distribution and adaptability to varied market needs.
The company's emphasis on quality assurance and safety standards elevates its reputation in the pharmaceutical space, particularly in the realm of vaccinations. Furthermore, Pfizer has a history of strategic mergers and acquisitions that have expanded its product lines and research capacities, enhancing its competitive edge in the global vaccine market. With a commitment to innovation, Pfizer continues to invest in advanced technologies and collaborative research initiatives aimed at improving its shingles vaccine offerings and ensuring its sustained growth in the market.
Recent developments in the Global Shingles Vaccine Market reflect vigorous activity among key players such as Merck and Co, Pfizer, and AbbVie. In July 2023, Merck received approval from health authorities for a new shingles vaccine, enhancing its product portfolio significantly. Pfizer has been advancing its research efforts, focusing on mRNA technology for vaccine enhancement, which could transform treatment efficacy. Meanwhile, on the growth front, it was noted in August 2023 that the global market valuation for shingles vaccines had surged, attributed to increased health investments and public awareness surrounding shingles.
Major companies have been ramping up their Research and Development efforts to launch more effective vaccines, with combined annual growth rates expected to rise given the rising elderly population susceptible to shingles. In mergers and acquisitions, no significant activities have been reported recently among the listed companies. The market remains poised for growth, guided by ongoing technological advancements and collaborations. Enhancements in vaccine formulations from companies such as GlaxoSmithKline and Astellas Pharma are anticipated to further stimulate the Global Shingles Vaccine Market in the coming years. Stakeholder engagement continues to be pivotal in addressing public health needs related to shingles.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 3.64(USD Billion) |
| MARKET SIZE 2024 | 3.89(USD Billion) |
| MARKET SIZE 2035 | 8.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.78% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Merck and Co, Pfizer, VBI Vaccines, Daiichi Sankyo, Imunogenetics, Bavarian Nordic, AbbVie, Eli Lilly, Johnson and Johnson, Novartis, Regeneron Pharmaceuticals, Astellas Pharma, AstraZeneca, GlaxoSmithKline, Sanofi |
| SEGMENTS COVERED | Vaccine Type, Age Group, Administration Route, End User, Regional |
| KEY MARKET OPPORTUNITIES | Growing aging population, Increased awareness campaigns, Expanding vaccine accessibility, Emergence of new vaccine technologies, Rising preventive healthcare focus |
| KEY MARKET DYNAMICS | Rising elderly population, Increasing awareness campaigns, Advancements in vaccine technology, Growing healthcare expenditure, Strong government support |
| COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Global Shingles Vaccine Market is expected to be valued at 3.89 USD Billion by 2024.
The market is projected to grow at a CAGR of 6.78% from 2025 to 2035.
The market is expected to reach approximately 8.0 USD Billion by 2035.
North America is expected to dominate the market with a valuation of 3.077 USD Billion in 2035.
The Live Attenuated Vaccine segment is projected to be valued at 2.5 USD Billion by 2035.
Major players include Merck and Co, Pfizer, and Bavarian Nordic among others.
The Recombinant Vaccine segment is expected to reach a market size of 3.5 USD Billion by 2035.
The Subunit Vaccine segment is valued at 0.69 USD Billion in the year 2024.
Europe is expected to have a market size of 0.875 USD Billion in 2024.
The South American market is anticipated to be valued at 0.703 USD Billion by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
